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Response to Letter to the Editor: “Transdermal buprenorphine plus oral
paracetamol vs an oral codeine–paracetamol combination for osteoarthritis of
hip and/or knee: a randomised trial. Comments on the article by Conaghan et al.”We thank Endenburg and colleagues for their interest in our trial1
and they raise a number of important issues. Aquestionwas raised on
how optimal pain control with minimal side effects was deﬁned
within the study. This was a collaborative judgement between the
Investigators and patients. Investigators would up or down titrate
the subjects’ dose at the end of each titration week based on escape
medication use, pain scores and reported adverse events. If either
the investigator or the subject were unsure as to whether optimum
pain control had been achieved, the patient would remain on the
same dose for a further week. Clearly this dialogue included indi-
vidual patient acceptance of a given level of side effects.
In order to address the question regarding the (expectedly
large) number of patients who were lost to follow up, the full anal-
ysis population was also presented in the original publication for
the primary endpoint. The missing box-scale (BS)-11 pain scores
and escape medication use from the subject diary cards were
replaced by the last observation carried forward (LOCF). Missing
observations due to discontinuation were extrapolated to study
completion (Day 84, Week 12).
We can provide further information on the baseline patient
characteristics. There were no data collected on the patient’s level
of education, duration or severity of osteoarthritis (OA). Patients
were eligible for entry into the study if they had a clinical diagnosis
of OA. The severity of OAwas not recorded, as a pain score of 5 on
the BS-11 pain scale at study entry was used as one of the entry
criteria for assessing eligibility for inclusion within the study. The
primary pain site for patients entering the study was OA of the
hip(s) and/or knees. Body mass index was similar between groups
with a mean weight at baseline of 81.35 kg in the 7-day buprenor-
phine patch plus oral paracetamol group and 83.54 kg in the co-
codamol group. The WOMAC questionnaire was an exploratory
analyses and the mean scores for all components of the WOMAC
questionnaire showed that subjects in both treatment groups had
a decrease between baseline and the end of the observation period.
At baseline mean (SD – standard deviation) scores were 174.2
(52.71) in the 7-day buprenorphine patch plus oral paracetamol
group and 184.1 (50.31) in the co-codamol group. By the end of
the titration period, these had decreased to 85.5 (53.81) and
104.8 (50.31), respectively. At the end of the assessment period,
the scores were 130.9 (73.91) in the 7-day buprenorphine patch
plus oral paracetamol group and 141.2 (71.05) in the co-codamolDOI of original article: 10.1016/j.joca.2011.11.018.
1063-4584/$ – see front matter  2012 Osteoarthritis Research Society International. Pu
doi:10.1016/j.joca.2011.12.011tablets group. Compliance was not a formal endpoint of the study.
However compliance was shown to be poor for anti-emetic use.
Patient diaries and returned clinical supplies indicated that many
patients did not take these as advised.
With respect to the total number of patients that were screened,
the protocol didn’t stipulate the collection of numbers screened or
reasons for screening ‘failure’. Patients were informally screened by
a general practitioner going through the entry criteria with the
patient. All patients were enrolled at formal screening, so we
have no data on screening ‘failures’.
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